Eric Rademacher
University of Cincinnati
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Eric Rademacher.
Stroke | 2009
Dawn Kleindorfer; Jane Khoury; Joseph P. Broderick; Eric Rademacher; Daniel Woo; Matthew L. Flaherty; Kathleen Alwell; Charles J. Moomaw; Alex Schneider; Arthur Pancioli; Rosie Miller; Brett Kissela
Background and Purpose— Delay in seeking medical attention after stroke symptom onset is the most important reason for low rates of thrombolytic use for ischemic stroke (IS) in the United States. This may be related to poor recognition of stroke symptoms, or to lack of awareness of time-sensitive stroke treatments. We describe public knowledge of t-PA as a treatment for IS, as well as changes over time in knowledge of stroke warning signs (WS) and risk factors (RF). Methods— Survey respondents were drawn from our biracial population of 1.3 million using random-digit dialing in 1995, 2000, and 2005 to reflect the age, race, and gender distribution of stroke patients, based on an ongoing stroke incidence study in the same region. They were asked open-ended questions regarding stroke WS, RF, and, in 2005, specific questions regarding t-PA. Comparisons over time were made using &khgr;2 analysis, and were corrected for multiple comparisons. Results— Over the 10-year study period, 6209 surveys were completed. Knowledge of WS and RF improved between 1995 and 2000. Between 2000 and 2005, knowledge did not improve significantly; however, there was a significant improvement in knowledge of 3 warning signs (12% in 1995 vs 16% in 2005, P=0.0004). In 2005, only 3.6% of those surveyed were able to independently name t-PA or “clot buster” when asked: “Suppose you were having a stroke. Do you know of any medication your doctor could give you into the vein to increase your chance of recovering from a stroke?”-although 19% claimed to have heard of t-PA once it was mentioned to them. Conclusion— Despite numerous national stroke public awareness campaigns, public knowledge of stroke WS and RF has not improved over the last 5 years. In addition, knowledge of t-PA as a treatment for IS is extremely poor. Public awareness messages in the future should focus on the possibility of urgent treatments, in addition to stroke WS and RF, so the public can translate their knowledge into action and present to medical attention more quickly. This may be the highest yield approach to increasing rates of treatment of IS with t-PA.
Stroke | 2013
Daniel Woo; Jonathan Rosand; Chelsea S. Kidwell; Jacob L. McCauley; Jennifer Osborne; Mark W Brown; Sandra E. West; Eric Rademacher; Salina P. Waddy; Jamie N. Roberts; Sebastian Koch; Nicole R. Gonzales; Gene Sung; Steven J. Kittner; Lee Birnbaum; Michael R. Frankel; Fernando D. Testai; Christiana E. Hall; Mitchell S.V. Elkind; Matthew Flaherty; Bruce M. Coull; Ji Y. Chong; Tanya Warwick; Marc Malkoff; Michael L. James; Latisha K Ali; Bradford B. Worrall; Floyd Jones; Tiffany Watson; Anne D. Leonard
Background and Purpose— Epidemiological studies of intracerebral hemorrhage (ICH) have consistently demonstrated variation in incidence, location, age at presentation, and outcomes among non-Hispanic white, black, and Hispanic populations. We report here the design and methods for this large, prospective, multi-center case–control study of ICH. Methods— The Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) study is a multi-center, prospective case–control study of ICH. Cases are identified by hot-pursuit and enrolled using standard phenotype and risk factor information and include neuroimaging and blood sample collection. Controls are centrally identified by random digit dialing to match cases by age (±5 years), race, ethnicity, sex, and metropolitan region. Results— As of March 22, 2013, 1655 cases of ICH had been recruited into the study, which is 101.5% of the target for that date, and 851 controls had been recruited, which is 67.2% of the target for that date (1267 controls) for a total of 2506 subjects, which is 86.5% of the target for that date (2897 subjects). Of the 1655 cases enrolled, 1640 cases had the case interview entered into the database, of which 628 (38%) were non-Hispanic black, 458 (28%) were non-Hispanic white, and 554 (34%) were Hispanic. Of the 1197 cases with imaging submitted, 876 (73.2%) had a 24 hour follow-up CT available. In addition to CT imaging, 607 cases have had MRI evaluation. Conclusions— The ERICH study is a large, case–control study of ICH with particular emphasis on recruitment of minority populations for the identification of genetic and epidemiological risk factors for ICH and outcomes after ICH.
Neurology | 2017
Tracy E. Madsen; Jane Khoury; Kathleen Alwell; Charles J. Moomaw; Eric Rademacher; Matthew L. Flaherty; Daniel Woo; Jason Mackey; Felipe De Los Rios La Rosa; Sharyl Martini; Simona Ferioli; Opeolu Adeoye; Pooja Khatri; Joseph P. Broderick; B. Kissela; D. Kleindorfer
Objective: Recent data suggest stroke incidence is decreasing over time, but it is unknown whether incidence is decreasing in women and men to the same extent. Methods: Within our population of 1.3 million, all incident strokes among residents ≥20 years old were ascertained at all hospitals during July 1993–June 1994 and calendar years 1999, 2005, and 2010. A sampling scheme was used to ascertain out-of-hospital cases. Sex-specific incidence rates per 100,000 among black and white participants, age- and race-adjusted, were standardized to the 2000 US Census population. Trends over time by sex were compared; a Bonferroni correction was applied for multiple comparisons. Results: Over the 4 study periods, there were 7,710 incident strokes; 57.2% (n = 4,412) were women. Women were older than men (mean ± SE 72.4 ± 0.34 vs 68.2 ± 0.32, p < 0.001). Incidence of all strokes decreased over time in men (263 [confidence interval 246–281] to 192 [179–205], p < 0.001) but not in women (217 [205–230] to 198 [187–210], p = 0.15). Similar sex differences were seen for ischemic stroke (men, 238 [223–257] to 165 [153–177], p < 0.01; women, 193 [181–205] to 173 [162–184], p = 0.09). Incidence of all strokes and of ischemic strokes was similar between women and men in 2010. Incidence of intracerebral hemorrhage and subarachnoid hemorrhage were stable over time in both sexes. Conclusions: Decreases in stroke incidence over time are driven by a decrease in ischemic stroke in men. Contrary to previous study periods, stroke incidence rates were similar by sex in 2010. Future research is needed to understand why the decrease in ischemic stroke incidence is more pronounced in men.
Journal of Stroke & Cerebrovascular Diseases | 2016
Monica L. Wagner; Jane Khoury; Kathleen Alwell; Eric Rademacher; Daniel Woo; Matthew L. Flaherty; Aaron Anderson; Opeolu Adeoye; Simona Ferioli; Brett Kissela; Dawn Kleindorfer; Joseph P. Broderick
BACKGROUND AND PURPOSE Antithrombotic medications are effective for ischemic stroke prevention, but stoppage of these medications is associated with an increased risk of thromboembolism. The frequency of antithrombotic withdrawal in the general population is unknown. METHODS We conducted a random phone sample of 2036 households in the Greater Cincinnati metropolitan area, representative of the stroke population by age, sex, and race, to determine the frequency of antithrombotic medication use and stoppage by physicians for medically indicated procedures. RESULTS Sixty-two percent of survey respondents reported that they were on an antithrombotic medication. Ten percent of participants reported that they had stopped taking their medication within the past 60 days for a medically indicated intervention. Of those who stopped taking the medication, it was more common for persons taking an anticoagulant to stop their medication (20%) than those taking an antiplatelet agent (9%). Colonoscopies and orthopedic surgeries were the most common reasons for withdrawal of antiplatelet agents, whereas orthopedic and vascular surgeries were the most common reason for withdrawal of anticoagulants. CONCLUSIONS Recommended discontinuation of antithrombotic medication for surgical or diagnostic procedures is common practice for persons in the community representative of a stroke population. Because stoppage of these medications is associated with an increased risk of thromboembolic stroke, further clinical trials are needed to determine best management practices in this setting.
JAMA | 2003
Alexander Schneider; Arthur Pancioli; Jane Khoury; Eric Rademacher; Alfred J. Tuchfarber; Rosemary Miller; Daniel Woo; Brett Kissela; Joseph P. Broderick
PS Political Science & Politics | 1995
Alfred J. Tuchfarber; Stephen Earl Bennett; Andrew Smith; Eric Rademacher
Stroke | 2018
Eric Rademacher; Jane Khoury; Brett Kissela; Daniel Woo; Matthew L. Flaherty; Pooja Khatri; Opeolu Adeoye; Simona Ferioli; Arthur Pancioli; Joseph P. Broderick; Dawn Kleindorfer
Stroke | 2014
Aaron Anderson; Jane Khoury; Eric Rademacher; Brett Kissela; Daniel Woo; Matthew L. Flaherty; Pooja Khatri; Opeolu Adeoye; Simona Ferioli; Arthur Pancioli; Joseph P. Broderick; Dawn Kleindorfer
Stroke | 2013
Joseph P. Broderick; Jane Khoury; Kathleen Alwell; Eric Rademacher; Aaron Anderson; Matthew L. Flaherty; Simona Ferioli; Daniel Woo; Felipe De Los Rios La Rosa; O. Adeoye; Pooja Khatri; Jason Mackey; Brett Kissela; Dawn Kleindorfer
Stroke | 2013
Aaron Anderson; Jane Khoury; Michael R. Frankel; Brett Kissela; Eric Rademacher; Matthew L. Flaherty; Daniel Woo; Pooja Khatri; Maria Knight Lapinski; Kathleen Alwell; Simona Ferioli; Sharyl Martini; Jason Mackey; Felipe De Los Rios La Rosa; Dawn Kleindorfer